{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:03Z","timestamp":1791357243311,"version":"4.3.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013739","name":"Pfizer Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008207","name":"AstraZeneca Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jad.2019.07.020","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T11:18:54Z","timestamp":1562325534000},"page":"600-606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials"],"prefix":"10.1016","volume":"257","author":[{"given":"Roger S.","family":"McIntyre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash S.","family":"Masand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willie","family":"Earley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2019.07.020_bib0049","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1176\/ajp.152.8.1130","article-title":"Antidepressant-induced manic and cyclic acceleration: a controversy revisited","volume":"152","author":"Altshuler","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2019.07.020_bib0016","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2000"},{"key":"10.1016\/j.jad.2019.07.020_bib0015","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.jad.2019.07.020_bib0036","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1192\/bjp.187.1.87","article-title":"Bipolarity\u2019 in bipolar disorder: distribution of manic and depressive symptoms in a treated population","volume":"187","author":"Bauer","year":"2005","journal-title":"Br. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2019.07.020_bib0018","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4088\/JCP.14m09081","article-title":"Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study","volume":"76","author":"Calabrese","year":"2015","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2019.07.020_bib0044","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1038\/tp.2014.43","article-title":"Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits","volume":"4","author":"Carnicella","year":"2014","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2019.07.020_bib0019","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bdi.12238","article-title":"The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial","volume":"17","author":"Durgam","year":"2015","journal-title":"Bipolar Disord."},{"issue":"3","key":"10.1016\/j.jad.2019.07.020_bib0041","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1176\/appi.ajp.2015.15020164","article-title":"An 8-Week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression","volume":"173","author":"Durgam","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2019.07.020_bib0020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jad.2017.03.032","article-title":"Tolerability of cariprazine in the treatment of acute bipolar I mania: a pooled post hoc analysis of 3 phase II\/III studies","volume":"215","author":"Earley","year":"2017","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.jad.2019.07.020_bib0042","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1176\/appi.ajp.2018.18070824","article-title":"Cariprazine treatment of bipolar depression: a randomized, double blind, placebo-controlled phase 3 study","volume":"176","author":"Earley","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2019.07.020_bib0043","doi-asserted-by":"crossref","unstructured":"Earley W., Burgess M.V., Khan B., et\u00a0al. Efficacy and safety of cariprazine in bipolar I depression: a double blind, placebo-controlled phase 3 study (Manuscript submitted). 2019.","DOI":"10.1111\/bdi.12852"},{"key":"10.1016\/j.jad.2019.07.020_bib0013","first-page":"108","article-title":"e. A double-blind comparison of valproate and lithium in the treatment of acute mania","volume":"148","author":"Freeman","year":"1992","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2019.07.020_bib0002","doi-asserted-by":"crossref","first-page":"692","DOI":"10.4088\/JCP.09m05291gre","article-title":"Subsyndromal depressive symptoms after symptomatic recovery from mania are associated with delayed functional recovery","volume":"72","author":"Gitlin","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"75\u201387","key":"10.1016\/j.jad.2019.07.020_bib0008","article-title":"Correlates of suicidal ideation in dysphoric mania","volume":"56","author":"Goldberg JF","year":"1999","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2019.07.020_bib0009","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1053\/comp.2000.7427","article-title":"Qualitative differences in manic symptoms during mixed versus pure mania","volume":"41","author":"Goldberg JF","year":"2000","journal-title":"Compr. Psychiatry"},{"issue":"8","key":"10.1016\/j.jad.2019.07.020_bib0005","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2165\/00023210-200721080-00001","article-title":"Epidemiology, diagnosis and management of mixed mania","volume":"21","author":"Gonzalez-Pinto","year":"2007","journal-title":"CNS Drugs"},{"issue":"213","key":"10.1016\/j.jad.2019.07.020_bib0046","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-3-642-25758-2_7","article-title":"The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions","volume":"213","author":"Gross","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.jad.2019.07.020_bib0034","series-title":"US Dept Health, Education, and Welfare Publication (ADM)","first-page":"218","article-title":"ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"issue":"3","key":"10.1016\/j.jad.2019.07.020_bib0010","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jad.2005.01.005","article-title":"Clinical and psychometric characterisation of depression in mixed mania: a report from the French National Cohort of 1090 manic patients","volume":"96","author":"Hantouche EG","year":"2006","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.jad.2019.07.020_bib0032","first-page":"29","article-title":"Wayne Macfadden and for the BOLDER study group. A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life","volume":"22","author":"Jean Endicott","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.jad.2019.07.020_bib0035","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jad.2019.07.020_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2011.06336.x","article-title":"Advances in bipolar disorder: selected sessions from the 2011 international conference on bipolar disorder","volume":"1242","author":"Kupfer","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jad.2019.07.020_bib0045","doi-asserted-by":"crossref","first-page":"S550","DOI":"10.1016\/S0924-977X(16)31595-4","article-title":"Efficacy of cariprazine on predominant negative symptoms of patients with schizophrenia: post hoc analysis of PANSS data, Marder factors, and cognition","volume":"26","author":"Marder","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2019.07.020_bib0006","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1744-859X-11-7","article-title":"Number of prior episodes and the presence of depressive symptoms are associated with longer length of stay for patients with acute manic episodes","volume":"11","author":"Martin-Carrasco","year":"2012","journal-title":"Ann. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2019.07.020_bib0030","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1176\/ajp.149.12.1633","article-title":"Clinical and research implications of the diagnosis of dysphoric mania or hypomania","volume":"149","author":"McElroy","year":"1992","journal-title":"Am. J. Psychiatry"},{"issue":"12","key":"10.1016\/j.jad.2019.07.020_bib0050","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S2215-0366(16)30264-4","article-title":"Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials","volume":"3","author":"McGirr","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2019.07.020_bib0023","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jad.2013.04.025","article-title":"DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data","volume":"150","author":"McIntyre","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2019.07.020_bib0039","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jad.2014.09.026","article-title":"The prevalence and illness characteristics of DSM-5-defined \"mixed feature specifier\" in adults with major depressive disorder and bipolar disorder: results from the international mood disorders collaborative project","volume":"172","author":"McIntyre","year":"2015","journal-title":"J Affect Disord"},{"issue":"2","key":"10.1016\/j.jad.2019.07.020_bib0001","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1017\/S1092852916000559","article-title":"Mixed features and mixed states in psychiatry: from calculus to geometry","volume":"22","author":"McIntyre","year":"2017","journal-title":"CNS Spectr."},{"issue":"4","key":"10.1016\/j.jad.2019.07.020_bib0026","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2019.07.020_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4068\/cmj.2017.53.1.1","article-title":"Mixed states in bipolar disorder: etiology, pathogenesis and treatment","volume":"53","author":"Muneer","year":"2017","journal-title":"Chonnam Med. J."},{"issue":"2","key":"10.1016\/j.jad.2019.07.020_bib0022","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jad.2013.04.032","article-title":"Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: a meta-analysis of placebo-controlled trials","volume":"150","author":"Muralidharan","year":"2013","journal-title":"J. Affect. Disord."},{"issue":"8","key":"10.1016\/j.jad.2019.07.020_bib0047","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.euroneuro.2013.05.006","article-title":"The potential role of dopamine D(3) receptor neurotransmission in cognition","volume":"23","author":"Nakajima","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.jad.2019.07.020_bib0040","doi-asserted-by":"crossref","first-page":"920","DOI":"10.4088\/JCP.15cs09841","article-title":"Florida best practice psychotherapeutic medication guidelines for adults with bipolar disorder: a novel, practical, patient-centered guide for clinicians","volume":"77","author":"Ostacher","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2019.07.020_bib0048","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/FBP.0000000000000070","article-title":"Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression","volume":"25","author":"Papp","year":"2014","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.jad.2019.07.020_bib0004","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0165-0327(97)01446-8","article-title":"Clinical subtypes of bipolar mixed states: validating a broader European definition in 143 cases","volume":"43","author":"Perugi","year":"1997","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2019.07.020_bib0021","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jad.2014.11.018","article-title":"Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial","volume":"174","author":"Sachs","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2019.07.020_bib0012","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jad.2014.10.061","article-title":"Prevalence rates and clinical implications of bipolar disorder \"with mixed features\" as defined by DSM-5","volume":"173","author":"Shim","year":"2015","journal-title":"J. Affect. Disord."},{"issue":"1\u20132","key":"10.1016\/j.jad.2019.07.020_bib0031","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jad.2009.10.007","article-title":"Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression","volume":"121","author":"Suppes","year":"2010","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2019.07.020_bib0028","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archpsyc.1997.01830130041008","article-title":"Depression during mania: treatment response to lithium or divalproex","volume":"54","author":"Swann","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2019.07.020_bib0027","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/j.2051-5545.2009.tb00245.x","article-title":"Continuum of depressive and manic mixed states in patients with bipolar disorder: quantitative measurement and clinical features","volume":"8","author":"Swann","year":"2009","journal-title":"World Psychiatry"},{"issue":"12","key":"10.1016\/j.jad.2019.07.020_bib0029","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/archpsyc.1990.01810240026005","article-title":"Outcome in mania 4-year prospective follow-up of 75 patients utilizing survival analysis","volume":"47","author":"Tohen","year":"1990","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2019.07.020_bib0003","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1192\/bjp.bp.105.020321","article-title":"Influence of sub-syndromal symptoms after remission from manic or mixed episodes","volume":"189","author":"Tohen","year":"2006","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2019.07.020_bib0024","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jad.2014.06.039","article-title":"Efficacy of olanzapine in the treatment of bipolar mania with mixed features defined by DSM-5","volume":"168","author":"Tohen","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2019.07.020_bib0011","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/00023210-200317070-00003","article-title":"Suicidal behaviour in bipolar disorder: risk and prevention","volume":"17","author":"Tondo L","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2019.07.020_bib0007","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jad.2017.09.006","article-title":"Mixed symptoms in major depressive and bipolar disorders: a systematic review","volume":"225","author":"Vazquez","year":"2018","journal-title":"J. Affect. Disord."},{"issue":"1\u20133","key":"10.1016\/j.jad.2019.07.020_bib0038","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jad.2009.12.019","article-title":"Prevalence of mixed mania using 3 definitions","volume":"125","author":"Vieta","year":"2010","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2019.07.020_bib0037","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jad.2013.12.031","article-title":"Phenomenology of manic episodes according to the presence or absence of depressive features as defined in DSM-5: results from the IMPACT self-reported online survey","volume":"156","author":"Vieta","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2019.07.020_bib0025","unstructured":"VRAYLAR (cariprazine) [package insert]. Irvine, CA: Allergan plc; 2019."},{"key":"10.1016\/j.jad.2019.07.020_bib0033","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity, and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032718322092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032718322092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:36:21Z","timestamp":1759023381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032718322092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":50,"alternative-id":["S0165032718322092"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2019.07.020","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2019.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}